<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T17:04:25Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/5774" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/5774</identifier><datestamp>2024-12-13T10:06:47Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>SEOM clinical guidelines in advanced and recurrent breast cancer (2018)</dc:title>
   <dc:creator>Chacón López‑Muñiz, J. I.</dc:creator>
   <dc:creator>de la Cruz-Merino, Luis</dc:creator>
   <dc:creator>Gavilá Gregori, Joaquín</dc:creator>
   <dc:creator>Martínez Dueñas, E.</dc:creator>
   <dc:creator>Antunes de Melo Oliveira, Ana Mafalda</dc:creator>
   <dc:creator>Seguí Palmer, M. A.</dc:creator>
   <dc:creator>Bellet Ezquerra, Meritxell</dc:creator>
   <dc:contributor>Institut Català de la Salut</dc:contributor>
   <dc:contributor>[Chacón López-Muñiz JI] Servicio de Oncología Médica, Hospital Virgen de la Salud, Avda. de Barber, 30, 45004 Toledo, Spain. GEICAM, Madrid, Spain. [de la Cruz Merino L] Servicio de Oncología Médica, Medicine Department, Hospital Virgen Macarena, University of Sevilla, Seville, Spain. [Gavilá Gregori J] Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain. [Martínez Dueñas E] Servicio de Oncología Médica, Hospital Provincial de Castellón, Castellón, Spain. [Oliveira M, Bellet Ezquerra M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Seguí Palmer MA] Servicio de Oncología Médica, Corporació Sanitaria Parc Tauli, Sabadell, Barcelona, Spain</dc:contributor>
   <dc:contributor>Vall d'Hebron Barcelona Hospital Campus</dc:contributor>
   <dc:subject>Mama - Càncer - Prognosi</dc:subject>
   <dc:subject>Metàstasi</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::/therapy</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis</dc:subject>
   <dc:subject>ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::/terapia</dc:subject>
   <dc:subject>ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico</dc:subject>
   <dc:description>Recurrència loco-regional; Càncer de mama; Pautes</dc:description>
   <dc:description>Recurrencia loco-regional; Cáncer de mama; Pautas</dc:description>
   <dc:description>Loco-regional recurrence; Breast cancer; Guidelines</dc:description>
   <dc:description>Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to progression and the overall survival. However, too much information has been produced in the last 2 years, so a well-based guideline is a valuable document in treatment decision making. The SEOM guidelines are intended to make evidence-based recommendations on how to manage patients with advanced and recurrent breast cancer to achieve the best patient outcomes based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the United States Preventive Services Task Force guidelines methodology was selected as reference.</dc:description>
   <dc:date>2021-03-19T09:39:54Z</dc:date>
   <dc:date>2021-03-19T09:39:54Z</dc:date>
   <dc:date>2019-01</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol. 2019 Jan;21(1):31–45.</dc:identifier>
   <dc:identifier>1699-3055</dc:identifier>
   <dc:identifier>https://hdl.handle.net/11351/5774</dc:identifier>
   <dc:identifier>10.1007/s12094-018-02010-w</dc:identifier>
   <dc:identifier>30617924</dc:identifier>
   <dc:identifier>000456179300004</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/5774</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Clinical and Translational Oncology;21(1)</dc:relation>
   <dc:relation>https://link.springer.com/article/10.1007%2Fs12094-018-02010-w</dc:relation>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Springer</dc:publisher>
   <dc:source>Scientia</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>